Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
abiraterone acetate, Quantity: 500 mg
Janssen-Cilag Pty Ltd
Abiraterone acetate
Tablet, film coated
Excipient Ingredients: lactose monohydrate; croscarmellose sodium; sodium lauryl sulfate; silicified microcrystalline cellulose; hypromellose; magnesium stearate; silicon dioxide; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black
Oral
60 tablets
(S4) Prescription Only Medicine
ZYTIGA is indicated in combination with prednisone or prednisolone for the treatment of: ? newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT), or ? patients with metastatic advanced prostate cancer (castration resistant prostate cancer, mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT) or ? patients with mCRPC who have received prior chemotherapy containing a taxane.
Visual Identification: Purple oval shaped film-coated tablet debossed with AA on one side and 500 on the other side.; Container Type: Blister Pack; Container Material: PVC/PE/PVDC/Al; Container Life Time: 3 Years; Container Temperature: Store below 30 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Licence status A
2017-02-17
ZYTIGA® (210818) CMI 1 ZYTIGA ® TABLETS _abiraterone _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about ZYTIGA tablets. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you being given ZYTIGA against the benefits this medicine is expected to have for you. IF YOU HAVE ANY CONCERNS ABOUT BEING GIVEN ZYTIGA ASK YOUR DOCTOR. KEEP THIS LEAFLET WHILE YOU ARE TAKING ZYTIGA. You may need to read it again. WHAT ZYTIGA IS USED FOR ZYTIGA is used to treat prostate cancer that has spread to other parts of the body. It reduces the levels of the sex hormone testosterone. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY ZYTIGA HAS BEEN PRESCRIBED FOR YOU. THIS MEDICINE IS AVAILABLE ONLY WITH A DOCTOR'S PRESCRIPTION. ZYTIGA is not addictive. BEFORE YOU TAKE ZYTIGA _WHEN YOU MUST NOT USE IT: _ DO NOT TAKE ZYTIGA: • if you are allergic (hypersensitive) to abiraterone, or other ingredients of ZYTIGA. See Product Description at the end of this leaflet for a list of ingredients. DO NOT TAKE ZYTIGA: • if the packaging is torn or shows signs of tampering. • if the expiry date (month and year) printed on the pack has passed. If you take ZYTIGA after the expiry date it may not work. DO NOT TAKE ZYTIGA: • if you are pregnant or maybe potentially pregnant ZYTIGA is not for use in women and children. • if you have severe liver failure ZYTIGA should not be used in patients with severe liver failure. Ask your doctor if you have questions. • if you are being treated with XOFIGO ZYTIGA and XOFIGO, a radiation therapy, should not be used together. _BEFORE YOU START TO USE IT: _ TELL YOUR DOCTOR IF YOU HAVE OR HAVE HAD ANY MEDICAL CONDITIONS, ESPECIALLY THE FOLLOWING: PROBLEMS WITH YOUR LIVER You should not take ZYTIGA if you have moderate or severe liver disease. Your doctor will decide whether ZYTIGA can be used if you have a mild Read the complete document
(CCDS210319) 1 ZYTIGA (210818) API AUSTRALIAN PRODUCT INFORMATION ZYTIGA ® ( ABIRATERONE ACETATE) TABLETS 1. NAME OF THE MEDICINE Abiraterone acetate 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ZYTIGA tablets contain either 250 mg or 500 mg of the active ingredient abiraterone acetate. Excipient(s) with known effect: Contains sugars as lactose. The 250 mg and 500 mg tablets contain 198.65 mg and 253.2 mg of lactose monohydrate respectively. For a full list of excipients, see section 6.1 List of Excipients. 3. PHARMACEUTICAL FORM ZYTIGA 250 mg uncoated tablets are white to off-white, oval-shaped tablets, debossed with “AA250” on one side. ZYTIGA 500 mg film-coated tablets are purple, oval-shaped, film-coated tablets, debossed with “AA” on one side and “500” on the other. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS ZYTIGA is indicated in combination with prednisone or prednisolone for the treatment of: • newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT), or • patients with metastatic advanced prostate cancer (castration resistant prostate cancer, mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT) or • patients with mCRPC who have received prior chemotherapy containing a taxane. 4.2 DOSE AND METHOD OF ADMINISTRATION The recommended dosage of ZYTIGA is 1 g (either two 500 mg tablets or four 250 mg tablets) as a single daily dose that MUST NOT BE TAKEN WITH FOOD. ZYTIGA tablets must be taken as a single dose once daily on an empty stomach. ZYTIGA must be taken at least two hours after eating and food must not be eaten for at least one hour after taking ZYTIGA. The tablets must be swallowed whole with water (see section 5.2 Pharmacokinetic Properties – Absorption). Product Information - Australia (CCDS210319) 2 ZYTIGA (210818) API DOSAGE OF PREDNISONE OR PREDNISOLONE For hormone sensitive prostate cancer (mHSPC), ZYTIGA is used with 5 mg prednisone or predni Read the complete document